If you are interested in learning about the latest findings of a new pancreatic cancer miracle cure, you've come to the right place. We'll discuss the treatments available, their side effects, and how to avoid the recurrence of pancreatic cancer. There are now several promising treatments that have shown great
A 3.5 cm solid polycyclic mass that isn't malignant is called an SSCA. It's a precursor lesion that isn't harmful to the pancreas and can signify a benign pancreatic tumor. Read on to learn more. Here is a breakdown of the different types of SSCA. Malignant tumors spread and
Pancreatic ductal adenocarcinoma (PDA) is lethal cancer with overall survival of six months. Although numerous phase 3 trials have failed to improve overall survival, some patients have responded to drugs used in other malignancies. Although there are no established molecular subtypes of PDA, studies in other solid tumors have revealed
Read on to learn more. Below are some causes, symptoms, and test results for Ca 199 elevation. This article can also help you decide whether to seek further diagnostic testing for Ca 199 elevation. In addition, it will give you a better idea of what to expect from the test
Genetic testing is recommended if you suspect you may have hereditary pancreatic cancer. This test looks for alterations in the DNA, which are present in all parts of the body. These alterations are identical from person to person and can affect treatment options. Genetic testing may cost thousands of dollars,
There are several different types of pancreatic cancer surgery. These include the Whipple procedure, Pylorus-preserving pancreaticoduodenectomy, and palliative bypass surgery. Before deciding which surgery is best for you, you must know a bit about each type of surgery. This article will provide some basic information about each type of surgery.
Although pancreatic ductal adenocarcinoma (PDA) is one of the most aggressive solid tumours, it is not genetically homogeneous. While Molecular PDA subtypes have been proposed but are not yet driving clinical treatment decision-making, we know that the tumour microenvironment plays a significant role in the progression and response to chemotherapy.